[vc_row][vc_column][vc_message]Check back regularly for additional information on Pre-Conference tracks[/vc_message][vc_column_text]

Wednesday May 27, 2020

[/vc_column_text][vc_empty_space height=”15″][vc_column_text][/vc_column_text][vc_empty_space height=”15″]

GRP Workshop

[/vc_column][/vc_row][vc_row][vc_column width=”3/4″][vc_column_text]The ISCT Global Regulatory Perspectives (GRP) workshop represents the diverse activities and partnerships between international regulatory bodies, industry, clinicians and academia.

Confirmed regulators include: FDA, EMA, PEI, PMDA and Swissmedic.
The highly interactive program will feature presentations and case studies on sterility controls, post manufacturing processing, combination products, and considerations following rapid approvals.[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Organizing Committee

[/vc_column_text][vc_empty_space height=”10px”][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]Karen Nichols, Esq.
Co-Chair
Magenta Therapeutics
United States

Yong Fan, MD
A2Z Reg Solutions
United States

Christopher Bravery, PhD
Consulting on Advanced Biologicals
United Kingdom

Scott Burger, MD
Advanced Cell & Gene Therapy
United States[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]Dominic Wall, PhD, FFSc(RCPA)
Co-Chair
Cell Therapies Pty Ltd, Peter MacCallum Cancer Centre
Australia

Srinivasan Kellathur, PhD
Advanced Therapy Products Unit, Health Sciences Authority
Singapore

Janet Macpherson, PhD
GE Life Sciences
Australia[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”10px”][vc_empty_space height=”10px”]

MSC Track

[vc_column_text]Organized by the ISCT MSC Scientific Committee, the Society’s scientific thought leadership on MSCs, this Pre-Conference Day Track provides the unique opportunity to bring together preeminent leaders from around the world to present their cutting-edge research and discuss key challenges related to discovery, development and clinical deployment of mesenchymal stromal cells.

[/vc_column_text][vc_column_text]

Organizing Committee

[/vc_column_text][vc_empty_space height=”10px”][/vc_column][/vc_row][vc_row][vc_column width=”1/3″][vc_column_text]Jacques Galipeau, MD
Co-Chair
University of Wisconsin-Madison
United States[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text]Mauro Krampera, MD
Co-Chair
University of Verona
Italy[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text]Luc Sensebe, MD, PhD
Co-Chair
ISCT MSC Committee
France[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”10px”]

Cell Processing Track

[vc_column_text]Join the journey from ‘Needle to Needle’ as the 2020 Cell Processing Track features a carefully curated program offering a unique look into the production of cell-based products, with a focus on novel processing techniques including gene editing, cell activation and expansion  and characterization by flow cytometry. This practical workshop will provide delegates an opportunity to dig into the details of what it takes to bring a product from bench to bedside.

[/vc_column_text][vc_column_text]

Organizing Committee

[/vc_column_text][vc_empty_space height=”10px”][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]Ruud Hulspas, PhD
Cellular Technologies Bioconsulting, LLC
Netherlands

Mara Neal, SH(ASCP)MT, MS, MBA
Cook Biotech
United States[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]Vicki Antonenas, MSc
Westmead Hospital
Australia

Paul Wallace, PhD
Roswell Park Comprehensive Cancer Center
United States[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”10px”]

Investigators to Investors (i to i)

[/vc_column][/vc_row][vc_row][vc_column width=”3/4″][vc_column_text]The inaugural investigators to investors (i to i) pre-conference track will bring together cell and gene therapy investors for a half-day educational event providing unparalleled access to cell and gene therapy key opinion leaders. The track will commence with a state of the industry overview and panel discussion covering topics crucial to investor due diligence, followed by meet the experts style session where attendees will have the opportunity to meet with the experts of their choosing for roundtable discussions.  

More information on featured key opinion leaders is coming soon.[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

Co-Chairs

[/vc_column_text][vc_empty_space height=”10px”][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_column_text]Bill Milligan 
Steminent Biotherapeutics
Canada/Taiwan[/vc_column_text][/vc_column][vc_column width=”1/2″][vc_column_text]Patrick Rivers, MBA
Aquilo Capital
United States[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]

ISCT-Cord Blood Connect

in partnership with WMDA